

patient setting. For outpatient procedures where volatile agents should probably be avoided (such as a midtrimester abortion), these adjunctive IV infusion techniques are simple to use and associated with a patient's rapid recovery and prompt discharge from the ambulatory surgery facility. With the increasing popularity of IV anesthetics, infusion pumps may soon become standard equipment on anesthesia machines.

PAUL F. WHITE, PhD, MD

REFERENCES

- Blitt C: Nitrous-narcotic-relaxant anesthesia vs. volatile anesthesia in the adult surgical outpatient, chap 5, *In* Brown BR Jr (Ed): *Contemporary Anesthesia Practice—Vol 1, Outpatient Anesthesia*. Philadelphia, FA Davis, 1978, pp 45-46
- Coe V, Shafer A, White PF: Techniques for administering alfentanil during outpatient anesthesia—A comparison with fentanyl. *Anesthesiology* 1983 Sep; 59(suppl):A347
- Prys-Roberts C, Sear JW, Low JM, et al: Hemodynamic and hepatic effects of methohexital infusion during nitrous oxide anesthesia in humans. *Anesth Analg* (Cleve) 1983 Mar; 62:317-323
- White PF: Continuous infusions of thiopental, methohexital or etomidate as adjuvants to nitrous oxide for outpatient anesthesia. *Anesth Analg* (Cleve), in press
- White PF: Use of continuous infusion versus intermittent bolus administration of fentanyl or ketamine during outpatient anesthesia. *Anesthesiology* 1983 Oct; 59:294-300

Perfluorochemical Emulsion— 'Artificial Blood': What Is It?

LELAND CLARK dramatically proved the oxygen-carrying ability of perfluorochemicals by completely submerging a mouse in the liquid for 20 minutes and having it survive. These inert liquids have extremely high oxygen solubilities, about 20 times that of water—that is, 45 ml per dl at 760 torr oxygen partial pressure (tension; PO_2) and 37°C; perfluorochemicals are also immiscible in water and are acutely toxic when given intravenously because they form a bolus that acts as a pulmonary embolus. In 1968 it was shown that a fine emulsion of perfluorochemical in saline solution could act as an erythrocyte substitute in rats that have had exchange transfusions. The first human volunteers received the perfluorochemical emulsion, Fluosol-DA (20%), in 1979. Fluosol-DA has 14 grams per dl of perfluorodecalin and 6 grams per dl of perfluorotripropylamine emulsified in a solution of salts and hydroxyethyl starch. Because Fluosol-DA contains only 20 grams per dl of perfluorochemical with an approximate density of 1.8 grams per ml, in a patient having a complete exchange transfusion (fluorocrit about 12%, ml per dl of perfluorochemical in the plasma) at 500 torr arterial oxygen partial pressure (Pao_2), the perfluorochemical would carry about 6 ml per dl of oxygen. This may seem small compared with a normal arterial oxygen content of blood at room air of 20 ml per dl; but because the perfluorochemical transports oxygen by direct solubility as does plasma, nearly all the oxygen in the perfluorochemical is consumed. That is, if an exchange-transfused patient had an arterial-venous oxygen content difference of 4 ml per dl, the mixed venous PO_2 would be more than 150 torr.

Recent clinical studies in the United States and

Japan have confirmed that perfluorochemicals do transport the expected volume of oxygen and in spite of the small amounts of perfluorochemical given (fluorocrit 3%), there were significant increases in oxygen content, oxygen consumption and mixed venous hemoglobin saturation. The perfluorochemical is cleared by expiration and has a plasma half-life of about 18 hours. As an erythrocyte substitute, perfluorochemical emulsions will only be beneficial in acute emergencies until blood is available. Because perfluorochemicals carry oxygen by simple solubility like plasma, the amount of oxygen carried is directly related to the Pao_2 . It has been shown in a clinical study that a significant increase in oxygen content could only be measured when the perfluorochemical was in the presence of high Pao_2 values (more than 300 torr).

One of the most intriguing properties of perfluorochemical emulsions is the extremely small size of the emulsion droplets, 0.1 micron (1/70 the size of an erythrocyte). With the potential to transport more oxygen through small constricted blood vessels, these fluids may be beneficial in any acute ischemic disease process. Glogar and co-workers showed a significant myocardial protective effect when these fluids were given in an animal model of myocardial infarction. Peerless and colleagues found similar results in an animal model of acute cerebral ischemia.

Perfluorochemical emulsions are intriguing new fluids that should be thought of as "supercharged" plasma and not erythrocyte substitutes. They may support anemic patients but require high oxygen tensions. They will probably play a significant role in the future in emergency treatment of ischemic disease.

KEVIN K. TREMPER, MD

REFERENCES

- Glogar DH, Kloner RA, Muller J, et al: Fluorocarbons reduce myocardial ischemic damage after coronary occlusion. *Science* 1981 Mar 27; 211:1439-1441
- Mitsuno T, Ohyanagi H, Naito R: Clinical studies of a perfluorochemical whole blood substitute (Fluosol-DA)—Summary of 186 cases. *Ann Surg* 1982 Jan; 195:60-69
- Peerless SJ, Ishikawa R, Hunter IG, et al: Protective effect of Fluosol-DA in acute cerebral ischemia. *Stroke* 1981 Sep-Oct; 12:558-563
- Tremper KK, Friedman AE, Levine EM, et al: The preoperative treatment of severely anemic patients with a perfluorochemical oxygen-transport fluid, Fluosol-DA. *N Engl J Med* 1982 Jul 29; 307:277-283

Transcutaneous Oxygen Partial Pressure: A Continuous Noninvasive Monitor of Tissue Oxygenation

A TRANSCUTANEOUS OXYGEN SENSOR measures oxygen partial pressure (PO_2) noninvasively at the skin surface with the same Clark polarographic electrode that is used in conventional blood gas machines. For the sensor to record significant PO_2 values with fast response times on adult skin, the electrode must be heated to 44°C to 45°C. Heating the skin causes the stratum corneum to change structure, which is thought to increase its permeability to oxygen. Heating also causes hyperemia of the dermal capillary bed and is